CD20-BCMA Bispecific CAR Architecture for Robust B Cell Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases, such as systemic lupus erythematosus, are inadequate, with therapies like rituximab and obexelimab failing to meet primary endpoints in clinical trials, highlighting the need for more effective B cell depletion strategies.
Innovation Solution
Development of a bispecific chimeric antigen receptor (CAR) that targets both CD20 and BCMA, comprising specific antigen-binding regions and signaling domains, for use in genetically engineered T cells to selectively deplete B cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies like rituximab or obexelimab are used to deplete B cells, then B cell depletion is achieved, but clinical trials failed to meet primary endpoints indicating insufficient therapeutic effectiveness
Solution Approach 1:
The patent creates a bispecific CAR that can recognize and bind to two different B cell markers (CD19 and CD20) simultaneously, enabling a single T cell to target multiple B cell populations that express different marker combinations. This multi-functionality overcomes the limitation of monoclonal antibodies that target only one marker and fail to deplete all pathogenic B cells.
Solution Approach 2:
The invention merges the targeting capabilities of two separate monoclonal antibodies into a single bispecific CAR construct. By combining CD19 and CD20 recognition domains within one CAR, the system achieves synergistic B cell depletion that neither single-target therapy could accomplish alone, directly addressing the clinical failure of previous single-antigen approaches.
2Object-generated harmful factors
If B cells are depleted to treat autoimmune diseases, then autoantibody production is reduced, but current depletion methods are inadequate and fail to prevent organ damage
Solution Approach 1:
The bispecific CAR enables T cells to identify and eliminate B cells through dual recognition of CD19 and CD20 markers. This ensures more complete depletion of autoreactive B cell populations, thereby more effectively reducing autoantibody production and preventing the formation of pathogenic immune complexes that cause organ damage in autoimmune diseases.
3Ease of manufacture
If single-target CARs are used, then T cell engineering is simpler, but B cell depletion is insufficient to achieve therapeutic benefit
Solution Approach 1:
The patent combines CD19 and CD20 antigen-binding domains into a single bispecific CAR construct that can be introduced into T cells via standard viral transduction methods. While the molecular design is more complex than single-target CARs, the manufacturing process remains compatible with existing T cell engineering platforms, achieving enhanced depletion efficacy without requiring fundamentally new manufacturing approaches.
Data Source
AI summary
The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA. The CAR may comprise an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.